Correction to: Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

peer reviewe

Innovative method using the sensor kinect for motor functions evaluation in SMA Type 2 and 3 Children

International audienc

L’évaluation automatisée et ludique de la fonction motrice : le projet Kinect MFM

National audienc

L’évaluation automatisée et ludique de la fonction motrice : le projet Kinect MFM

National audienc

User-centered development of an information system in patient’s motor capacity evaluation

International audienceMany medical devices are created and rejected because of their lack of adequacy to the clinician needs and situation. The implication of a clinician in the design process may prevents the creation of solution than seems pushed to the users but in contrary create a solution calibrated to their usages. In this paper a UCD cycle was applied to the development of an information system for patients’ motor evaluation using the motion analysis sensor Kinect. The system should support the therapist in its evaluations and provide a way to improve the evaluation. The context exploration, requirements definition, so-lution proposition and adequacy evaluation was applied. The model allowed to emphasis the aspects that are important and were rightfully answered but also on the revision needs for a second cycle to generate an acceptable device

Distal motor function assessments of children with spinal muscular atrophy: the use of a tablets as a part of the proposed kinect-MFM study

International audienceIntroduction: Given the progress of research and management in the neuromuscular diseases, particularly in Spinal Muscular Atrophy (SMA), validated tools are needed to assess patients' motor function. These tools are fundamental in order to improve the understanding of the natural history and to quantify the impact of new therapeutics in these populations. The Motor Function Measure (MFM) is a validated scale for the measurement of functional motor capacities usable in all neuromuscular diseases. Purpose: Clinicians from a neuromuscular diseases reference center (Hospices Civils de Lyon, France) and G-SCOP research team (INP Grenoble, France) were developing the instrumented Kinect-MFM, an automated system to assess SMA patients' motor function using new and low cost technology. By using, these technologies, our objectives were to improve the quality and reproducibility of the MFM by suppressing subjectivity linked to heteroevaluation. Method: The first step of this work was to assess the relevance of the tablet to capture and measure distal motor functions during a MFM test. The second was to compare the scoring of MFM items provided by a therapist with the scoring provided by the system. Results: Three applications were developed on this system to allow the comparison. They show difficulties to reproduce exactly the same conditions than in the current MFM. The size, the sensitivity, the multipoint control and the accuracy of the tablet constitute some challenge we have to take up. Conclusions: the proposed tablet was initially user to control the complete system by the therapist. The complexity of measuring distal functions by the Kinect led us to use this technology to complete the MFM instrumented protocol researchers proposed

Hand Dexterity: Design for Automatic Evaluation of Item 18 of MFM Scale

International audienc

Design of Game Scenario Applicable to the Assessment of motor function based on MFM

National audienc

Scoring People With Spinal Muscular Atrophy on the Motor Function Measure Using the Microsoft Kinect

International audiencePurpose: Assess the ability of the Kinect to capture movement and posture of people with spinal muscular atrophy (SMA) during completion of 14 items of the Motor Function Measure, a validated functional rating scale for people with neuromuscular diseases. Methods: Multicenter feasibility study in which Motor Function Measure items were scored as usual by the participant's therapist during the completion (Score-T) while another therapist scored items based only on the visualization of digital data collected using the Kinect (Score-D). Agreement and disagreement were investigated. Results: Twenty people with SMA type 2 or 3 were participants; 142 items were recorded and analyzed. There was 31.7% agreement between Score-T and ScoreD for participants with SMA type 2, and 76.2% for those with SMA type 3. Conclusions: The results prevent us from considering the use of Kinect capture to deduce an automated scoring, but this device may be of interest to highlight potential compensations

Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.

peer reviewed("[en] OBJECTIVE: To evaluate sensitivity to change and discriminant validity of the 20-item Motor Function Measure (MFM-20) in 2-7-year-old patients with spinal muscular atrophy types 1 (SMA1) or 2 (SMA2) treated with nusinersen. METHODS: Children aged 2 to 7 years old with SMA1 or SMA2 treated with nusinersen were assessed at least three times using the MFM-20 over an average follow-up time of 17 months. Evolution of 4-month-standardized MFM-20 scores was calculated for each MFM-20 domain (D1 standing and transfers, D2 axial and proximal, D3 distal) and for the total score (TS). RESULTS: Included in the study were 22 SMA1 subjects and 19 SMA2 subjects. Baseline MFM scores were significantly lower in patients with SMA1 than SMA2 (TS 29.5% vs. 48.3%, D1 4.5% vs. 10.6%, D2 43.6% vs. 72.6%, D3 51.2% vs. 75.0%). When considering the mean change during nusinersen treatment, standardized over a 4-month period, TS was improved for both SMA1 (+ 4.1%, SRM 1.5) and SMA2 (+ 2.8%, SRM 0.89) patients. For SMA1 patients, considerable changes were observed in D2 (+ 6.2%, SRM 0.89) and D3 (+ 6.0%, SRM 0.72), whereas the change in D1 was small (+ 0.5%, SRM 0.44). In SMA2 2 subjects, D3 was improved to a larger extent (+ 4.2%, SRM 0.53) than D1 (+ 1.8% SRM 0.63) or D2 (+ 3.2%, SRM 0.69). CONCLUSION: Our results validate use of MFM-20 to monitor function of young SMA1 and SMA2 subjects treated with nusinersen. Significant motor function improvements following treatment were observed in both SMA1 and SMA2 patients.","[en] ",""